The clinical data of a child with systemic lupus erythematosus (SLE) and hypophosphatasia (HPP) admitted to the Department of Pediatrics, the Second Hospital of Jilin University in December 2015 were retrospectively analyzed.The patient was a 10-year-old boy who was hospitalized because of fever and facial rashes in the past 4 days.He had a history of HPP for 7 years.His clinical manifestations included skeletal and dental dysplasia, oral ulcers, buccal erythema and renal lesions.Laboratory examination showed a low level of serum alkaline phosphatase, whole blood cell count decreased, antinuclear antibody(ANA) 1∶1 000, anti-double strand DNA antibodies positive, anticardiolipin antibodies positive, complement 3 (C 3) and C 4 decreased.Therefore, he was diagnosed with SLE.After glucocorticoid, immunosuppressant and symptomatic treatment, the child′s condition improved and he discharged from the hospital.He was followed up regularly, and died 2 years after the diagnosis of SLE.SLE complicated with HPP is extremely rare in clinical practice, and the symptoms may overlap.Hence these two diseases should be differentiated.

Objective:To evaluate the reliability and validity of Chinese version of Ureteral Stent-Related Symptom Questionnaire (USSQ) so as to provide a scientific tool for the symptom assessment of patients with indwelling ureteral stents.Methods:Following the translation principle of Brislin, the cultural adjustment of the questionnaire was completed according to the process of literal translation of the scale, back translation, expert committee discussion and pre-experiment, and the Chinese version of USSQ was formed. Inpatients with ureteral stents in the Urology Departments of 3 ClassⅢ Grade A hospitals in Urumqi from April 2018 to February 2019 were selected as research objects, and 485 questionnaires were collected by analyzing and testing the items and reliability and validity of the questionnaire.Results:Finally, 462 valid questionnaires were collected. The analysis results of the project suggested that the two items of S1 and S2 in the Chinese version of USSQ in the field of sexual life could be deleted ( P>0.05) , however, considering the rationality of the structure of the questionnaire, S1 should be retained. Cronbach's α coefficient of the questionnaire was 0.923, Cronbach's α coefficient of the six dimensions of urinary symptoms, physical pain, total health status, work performance, sexual life and additional problems was 0.703 to 0.918, retest reliability was 0.885, retest correlation coefficient of the six dimensions was 0.338 to 0.849 ( P<0.05) , and half reliability was 0.628. The content validity of the questionnaire was 0.887. Through exploratory factor analysis, the cumulative variance contribution rate of the nine principal factors was 68.995%. In the correlation analysis, except for the correlation coefficients in the field of sexual life and other fields were from 0.014 to 0.101 ( P>0.05) , the correlation coefficients in other dimensions were from 0.406 to 0.629 ( P<0.01) . The test results of criterion validity showed that the correlation coefficients of each dimension of the questionnaire with International Prostate Symptom Score (IPSS) , Incontinence Quality of Life Scale (I-QOL) and The 12-Item Short Form Health Survey (SF-12) were from 0.35 to 0.49 ( P<0.01) . Conclusions:In addition to the field of sexual life, the Chinese version of USSQ has good reliability and validity in the evaluation of symptoms in other fields, which can provide a basis for the investigation and improvement of related symptoms in patients with indwelling ureteral stents in China.

Objective: To compare the efficacy of induction chemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) for newly diagnosed young diffuse large B cell lymphoma (DLBCL) patients. Methods: The retrospective study was performed in 90 cases of young patients (≤60 years) with newly diagnosed DLBCL and an age-adjusted International Prognostic Index (aa-IPI) score of 2 or 3. All of them were treated with R-CHOP (32 cases, rituximab combined with CHOP), dose-intensive regimens (DA-EPOCH, Hyper CVAD/MA or ESHAP) combined with or without rituximab (25 cases), and consolidated with up-front auto-HSCT (33 cases), respectively. The efficacy and the potential predictors were evaluated. Results: ①The median age of 90 patients was 43 (18-60) years old. The median follow-up time was 42 (3-110) months. ②The 5-year progression-free survival (PFS) for R-CHOP group, dose-intensive chemotherapy group and auto-HSCT group were (33.5±10.7) %, (55.3±10.1) % and (65.8±13.6) % (P=0.012), the 5-year overall survival (OS) were (49.7±9.0) %, (61.6±10.2) % and (78.6±7.8) % (P=0.035), respectively. There was no significant difference in 5-years PFS and OS between the R-CHOP group and dose-intensive chemotherapy group (P=0.519, P=0.437) compared with that of the dose-intensive chemotherapy group, auto-HSCT group has higher 5-year PFS (P=0.042). ③ When stratified with IPI score, the high-risk group treated with auto-HSCT (26 cases) showed similar 5-years PFS and 5-years OS to those in the low-risk group with chemotherapy alone (12 cases were in R-CHOP group and 8 cases were in dose-intensive chemotherapy group) [5-years PFS were (62.3 ±14.3)%, (58.3 ±18.6)% and (51.4±18.7)%, respectively, P=0.686; 5-years OS were (69.2±13.9)%, (62.5±15.5)% and (58.3±18.6)%, respectively, P=0.592]. ④However, the high-risk group treated with auto-HSCT (26 cases) showed superior 5-years PFS (P=0.002) and 5-years OS (P=0.019) compared to the high-risk group with chemotherapy alone (20 cases were in R-CHOP group and 17 cases were in dose-intensive chemotherapy group) [5-years PFS were (62.3±14.3)%, (41.1±13.5)% and (21.9±11.6)%, respectively; 5-years OS were (69.2±13.9)%, (51.5%±14.0)% and (35.4±13.6)%, respectively]. ⑤In the univariate analysis, as a whole, patients diagnosed with GCB subtype had higher 3-years PFS (P=0.022) and 3-years OS (P=0.037) compared to non-GCB subtype patients; in subgroup analysis, patients diagnosed with GCB subtype had higher 3-years PFS and 3-years OS compared to non-GCB subtype both in R-CHOP group (P=0.030, P=0.041) and dose-intensive chemotherapy group (P=0.044, P=0.047), but not in auto-HSCT group (P=0.199, P=0.093). ⑥In the multivariate analysis, different molecular classification (GCB/non-GCB) was an independent predictor for PFS and OS both in R-CHOP group [HR=0.274 (95% CI 0.094-0.800), P=0.018; HR=0.408 (95% CI 0.164-1.015), P=0.045] and dose-intensive chemotherapy group [HR=0.423 (95% CI 0.043-1.152), P=0.048; HR=5.758 (95% CI 0.882-6.592), P=0.035]. However, there was no significant difference in PFS and OS for auto-HSCT group between GCB/non-GCB patients. Conclusion Induction chemotherapy followed by up-front auto-HSCT has significant effect on efficacy for young and untreated patients with high risk DLBCL. Combined with induction chemotherapy followed by up-front auto-HSCT could improve the prognosis of non-GCB patients.